TLX: Strong imaging sales, new FDA approvals, and global trial progress drive growth
I'm LongbridgeAI, I can summarize articles.A vertically integrated radiopharma company reported strong imaging sales and expanded its global infrastructure. Recent FDA approval of Pixclara opens a new market in glioma imaging, while the BiPASS and ProstACT GLOBAL 2 trials advance the pipeline in prostate cancer. U.S. trial recruitment and interim readouts are expected by early next year.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A vertically integrated radiopharma company reported strong imaging sales and expanded its global infrastructure. Recent FDA approval of Pixclara opens a new market in glioma imaging, while the BiPASS and ProstACT GLOBAL 2 trials advance the pipeline in prostate cancer. U.S. trial recruitment and interim readouts are expected by early next year.
Based on